Stem Cell Treatment Process in Japan
Booking a trip before you’ve confirmed the diagnosis, the exact product or plan, its legal status in Japan, the outcome measures, the full cost, and the follow-up you’ll need at home is a gamble. Get those answers first.
We support international patients with record preparation, appointment coordination, interpretation and follow-up handoff. All medical decisions are made by licensed physicians after individual review.
Imaging, laboratory results and prior treatment records should be reviewed together. A diagnosis name alone is rarely enough.
Before money changes hands
Get four answers in writing.
Exact plan
Cell source, processing, route, number of administrations and timing.
Legal status
PMDA-approved product, ASRM plan, clinical research, or another defined route.
Measured outcome
What will be measured, when it will be measured, and what result would matter.
The road from records to results
Eight steps from records to follow-up.
A complete record set gives the reviewing physician more context before any travel or procedural decision.
The exact sequence depends on the cell source and protocol, but these are the decisions that ought to be clear in your head before you move forward.
Send a complete record set
Diagnosis, imaging, laboratory results, current medicines, allergies, previous procedures and recent discharge summaries.
Define the question you need answered
State what has already been tried and which symptom, function or clinical result you most want clarified.
Individual physician review
The review should decide whether more testing is needed and whether the proposed approach is medically reasonable for your case.
Confirm the exact legal route
Ask for the product name or regenerative medicine plan information. Do not accept “approved in Japan” as the only explanation.
Complete required on-site testing
Testing varies by diagnosis and protocol. It may include laboratory work, imaging, infection screening or functional assessment.
Review written consent and cost
Confirm benefits being discussed, alternatives, known risks, important unknowns, total self-pay items, cancellation rules and follow-up.
Collection, processing or product preparation
Your own cells, donor-derived cells and approved commercial products follow different collection, manufacturing and release steps.
Administration and follow-up
Leave with the procedure summary, medicines, warning signs, contact instructions and a written schedule for repeat tests or functional checks.
What Japan has actually approved
Approval is product-specific and indication-specific.
PMDA reported 26 approved regenerative medical products as of May 20, 2026. That number covers cell therapies, CAR-T products, gene therapies and tissue-based products—it doesn’t mean there are 26 interchangeable stem-cell treatments for common chronic diseases.[1]
A registered regenerative medicine plan and a PMDA marketing approval are different legal concepts. Check the exact product or plan, not only the word “registered.”
The same diagnosis can have different stages, prior treatments and risk factors. Those details change what can reasonably be discussed.
Does your case actually fit?
Use a three-level check instead of a generic “yes or no.”
Evidence by condition
Do not carry evidence from one disease into another.
The cell type, route, timing and outcome measures that matter for spinal cord injury are not the same as those for heart failure, diabetes, knee disorders or ovarian function.
Got reports but not sure which details actually matter?
Send what you have and we’ll help you shape a shorter, sharper list of questions.
Case Study: Where the process diverges
Two approved products show how different the process can be.
These examples aren’t blanket recommendations. They show why you need the exact product name, indication and protocol before comparing costs or outcomes side by side.
Severe ischemic cardiomyopathy
RiHEART is an allogeneic iPS cell-derived cardiomyocyte sheet with conditional and time-limited approval. PMDA’s review describes three sheets transplanted onto the heart surface, generally by left thoracotomy, followed by three immunosuppressants for 90 days. Efficacy information was still considered limited at approval.[3]
Traumatic spinal cord injury
The original PMDA review relied on a 13-patient, single-site study without a control group. Twelve of 13 patients improved by at least one AIS grade, but PMDA explicitly noted the small sample, lack of control group and need for further post-marketing evaluation.[4]
Reading between the lines
One “success rate” cannot describe stem-cell care.
For a result to be useful, you need the diagnosis nailed down, plus the cell type or product, the route, baseline severity, the outcome measure, and a clear follow-up window.
If a claim gives a percentage but does not tell you who was treated, what was measured, what the comparison was and when the result was measured, it is not enough to estimate your own outcome.
validated pain and function scores, walking distance, rescue medication.
AIS, motor or functional scales, activities of daily living, rehabilitation exposure.
HbA1c, glucose profile, insulin or medication requirements, hypoglycemia.
condition-specific laboratory values, imaging, hospitalization or survival endpoints.
Imaging can support an assessment, but it should not replace symptoms, function, laboratory data and clinically meaningful endpoints.
There is no general stem-cell survival rate. Ask for the exact diagnosis, disease stage, time point, comparator and whether the endpoint was overall survival, progression-free survival, hospitalization or another outcome.
Use the same validated scale before and after the procedure. Recovery claims without a baseline score and follow-up schedule are difficult to interpret.
An MRI or CT change may be useful, but it should be read together with symptoms, function and clinical outcomes.
A laboratory marker matters only if it is clinically relevant to the diagnosis and interpreted in the context of medicines, disease stage and baseline values.
Individual stories cannot show how often a result occurs, what happens to patients who do not improve, or whether improvement came from other care.
Know the full cost
Ask for an itemized total, not a single headline price.
There’s no single Japan price for stem-cell care. The total shifts with the cell source, processing, number of visits, tests, medicines, administration route and follow-up.
If a proposal is self-pay, confirm what happens if the on-site review changes eligibility or the planned cell batch cannot be used.
Once you’re back home
The follow-up plan should already be written before you leave Japan.
A useful plan spells out what to measure, when to measure it, which symptoms need urgent attention, and what information to send back.
Collect the procedure summary, medicines, warning signs and relevant test results.
Complete the first planned symptom, laboratory or wound check if required.
Repeat the same baseline scale when the protocol specifies it.
Share agreed imaging, laboratory or functional results at the planned time points.
How we help
Practical support before, during and after your Japan visit.
Our service handles preparation, coordination and communication. We don’t diagnose, we don’t prescribe, we don’t decide who’s eligible, and we don’t promise any outcome.
Record preparation
Organize diagnosis, imaging, laboratory results, medication history and the questions that should be ready for review.
Appointment coordination
Coordinate requests and scheduling after the required information is ready.
Interpretation support
Help you communicate questions and understand answers across language barriers.
Follow-up handoff
Clarify which documents and results should be carried forward after the visit.
Where to go from here
Continue with the topic that matches your next decision.
Condition-specific information is more useful than broad claims about stem cells as a single category.
Sort these out before you go
Questions that can change the decision.
General information only. Individual eligibility, risk and follow-up depend on the exact diagnosis and proposed protocol.
Does “approved in Japan” mean my condition is approved?
How long does the process take?
What is the success rate?
Can I get a survival estimate?
What should I get before paying?
What should I take home?
Get ready before you book
Get a shorter, clearer list of what to send and what to ask next.
Already have a diagnosis and some reports? Send over what you’ve got. We can help turn scattered information into a shorter, more useful question list.
We provide information and coordination support only—no diagnosing, no prescribing, no medical eligibility decisions, and no guarantees. Medical decisions belong to a licensed physician reviewing your case.